The DOI matches its Crossref record.
Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate
Abstract
Objective: To determine cancer risk in a cohort of 459 rheumatoid arthritis (RA) patients treated with methotrexate in community practice. Methods: All RA patients who started methotrexate prior to June 1986 and were attending 1 of 6 rheumatologists were studied. Demographic data were matched to the State Cancer Registry to identify all malignancies (except nonmelanoma skin cancer) for 1983–1998, and to the National Death Index to identify all deaths to the end of 1999. Followup started on the date when methotrexate was started and ended either on the last confirmed date on which the patient was seen by the rheumatologist or at death. Standardized incidence ratios (SIRs) were calculated using state population cancer rates stratified by sex, age (in 5‐year groups), and calendar year. Results: There were 4,145 person‐years of followup (average 9.3 years). Eighty‐seven malignancies were identified (14 before, 64 during, and 9 after the followup period). There was an estimated 50% excess risk of malignancy among methotrexate‐exposed RA patients relative to the general population (SIR 1.5, 95% confidence interval [95% CI] 1.2–1.9), with a 3‐fold increase in melanoma (SIR 3.0, 95% CI 1.2–6.2), a 5‐fold increase in non‐Hodgkin's lymphoma (SIR 5.1, 95% CI 2.2–10.0), and an almost 3‐fold increase in lung cancer (SIR 2.9, 95% CI 1.6–4.8). Conclusion: Compared with the general population, methotrexate‐treated RA patients have an increased incidence of melanoma, non‐Hodgkin's lymphoma, and lung cancer. There may be a role for regular skin cancer screening for all RA patients, particularly those receiving immunosuppressive therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Fraenkel, L., Bathon, J. M., England, B. R., St.Clair, E. W., Arayssi, T., Carandang, K., Deane, K. D., Genovese, M., Huston, K. K., Kerr, G., et al. (2021) · Arthritis Care & Research · doi:10.1002/acr.24596 · Cited by 1,341
2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Fraenkel, L., Bathon, J. M., England, B. R., St.Clair, E. W., Arayssi, T., Carandang, K., Deane, K. D., Genovese, M., Huston, K. K., Kerr, G., et al. (2021) · Arthritis & Rheumatology · doi:10.1002/art.41752 · Cited by 1,042
Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review
Wang, W., Zhou, H., & Liu, L. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.027 · Cited by 562
Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysis
Simon, T. A., Thompson, A., Gandhi, K. K., Hochberg, M. C., & Suissa, S. (2015) · Arthritis Research & Therapy · doi:10.1186/s13075-015-0728-9 · Cited by 557
European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies
Annese, V., Beaugerie, L., Egan, L., Biancone, L., Bolling, C., Brandts, C., Dierickx, D., Dummer, R., Fiorino, G., Gornet, J. M., et al. (2015) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjv141 · Cited by 428
Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference
Kalb, R. E., Strober, B., Weinstein, G., & Lebwohl, M. (2009) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.11.906 · Cited by 368
BYKERK, V. P., AKHAVAN, P., HAZLEWOOD, G. S., SCHIEIR, O., DOOLEY, A., HARAOUI, B., KHRAISHI, M., LECLERCQ, S. A., LÉGARÉ, J., MOSHER, D. P., et al. (2012) · The Journal of Rheumatology · doi:10.3899/jrheum.110207 · Cited by 335
Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors
Lidar, M., Giat, E., Garelick, D., Horowitz, Y., Amital, H., Steinberg-Silman, Y., Schachter, J., Shapira-Frommer, R., & Markel, G. (2018) · Autoimmunity Reviews · doi:10.1016/j.autrev.2018.01.003 · Cited by 180
Metadata
- Authors
- Buchbinder, R., Barber, M., Heuzenroeder, L., Wluka, A. E., Giles, G., Hall, S., Harkness, A., Lewis, D., Littlejohn, G., Miller, M. H., Ryan, P. F. J., & Jolley, D.
- Venue
- Arthritis Care & Research
- Publisher
- Wiley
- Published
- 2008-05-30
- Volume
- 59
- Issue
- 6
- Pages
- 794-799
- ISSN
- 0893-7524 (ISSN-L)
- 1529-0123
- OpenAlex
- W2005490856
- Cited by
- 217
- References
- 0
- FWCI
- 8.79
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.